How does HIV infection affect the liver and what baseline and ongoing liver function testing, hepatitis screening, and management strategies are recommended for patients with HIV?

HIV Infection Impact on the Liver

All HIV-infected patients should be screened for hepatitis B and C coinfection at baseline, as these coinfections dramatically accelerate liver disease progression and represent the primary liver-related threat in this population. 1

Direct Effects of HIV on the Liver

HIV infection itself can cause liver damage even without viral hepatitis coinfection:

• HIV directly infects multiple liver cell types, leading to enhanced intrahepatic apoptosis, cellular activation, and progressive fibrosis 2
• HIV alters gastrointestinal tract permeability, resulting in elevated circulating lipopolysaccharide levels that further compromise liver function 2
• Liver-related diseases account for 13-18% of all-cause mortality in people living with HIV, making it one of the leading non-AIDS causes of death 3
• Even virologically suppressed patients on stable antiretroviral therapy remain at higher risk for liver pathology compared to the general population 3

Hepatitis B Coinfection: The Critical Concern

Between 6-13% of HIV-infected persons are coinfected with HBV, with higher rates in endemic regions like sub-Saharan Africa 1:

• HIV/HBV coinfected patients experience higher HBV DNA levels, lower rates of spontaneous HBeAg seroconversion, more severe liver disease, and increased liver-related mortality compared to HBV monoinfection 1
• Accelerated progression to cirrhosis, hepatocellular carcinoma, and hepatic decompensation occurs in coinfected patients 1, 4
• "Occult HBV" can occur where patients have high HBV DNA levels with anti-HBc positivity but negative HBsAg 1

Immune Reconstitution Hepatitis Risk

• Severe hepatitis flares can occur in coinfected patients with low CD4 counts when initiating highly active antiretroviral therapy (HAART) due to immune reconstitution 1
• This represents a critical monitoring period requiring close surveillance 1

Hepatitis C Coinfection: Accelerated Fibrosis

Up to one-third of HIV-infected patients are coinfected with HCV 5:

• HIV/HCV coinfected patients develop HCV-associated liver disease in a shorter time course than HCV monoinfection, with more rapid progression to cirrhosis and its complications 1, 5
• The average rate of HCV transmission from coinfected mothers to infants is approximately 15% (range 5-36%), higher than HCV monoinfection alone 1

Antiretroviral Therapy-Related Liver Toxicity

Drug-Specific Hepatotoxicity Risks

Nevirapine carries the highest risk of hepatotoxicity among antiretrovirals:

• 12.5% incidence of hepatotoxicity with 1.1% developing clinical hepatitis, and can cause fulminant hepatic necrosis and death 6
• Female patients have twice the risk of nevirapine-related hepatotoxicity compared to males 6
• Rechallenge with nevirapine after documented hepatotoxicity can be fatal and should be avoided 6

Protease inhibitors, especially ritonavir-containing regimens, can cause hepatotoxicity at any time during or after treatment 6

Nucleoside analogs (didanosine, stavudine) increase risk of lactic acidosis with hepatic steatosis even after discontinuation 6

Hepatotoxicity in Coinfected Patients

• Antiretroviral-associated liver enzyme elevations occur more frequently in HIV/HCV coinfected patients 1
• These elevations often do not require treatment modifications, and HAART should not be routinely withheld from coinfected patients 1
• Careful liver enzyme monitoring is mandatory, especially during the first 3-6 months of therapy 1

Long-Term ART and Liver Damage

• In patients with normal baseline liver function and no HBV/HCV coinfection, 12.41% developed grade II-IV liver enzyme elevation over 11 years of follow-up 7
• The highest incidence of liver damage occurs at 6-12 months of ART (15.16/100 person-years), then decreases and stabilizes after 2 years (average 3.65/100 person-years) 7
• Cumulative ART duration does not increase the risk of liver damage in patients without viral hepatitis coinfection 7

Baseline Screening Requirements

All HIV-infected patients must undergo comprehensive hepatitis screening 1:

For Hepatitis B:

• Test for both HBsAg AND anti-HBc (not just HBsAg alone) 1
• If either HBsAg or anti-HBc is positive, test for HBV DNA to detect occult HBV 1
• Patients negative for all HBV markers should receive hepatitis B vaccine 1
• Vaccine should be administered when CD4 counts are >200/μL as response is poor below this threshold 1
• Patients with CD4 <200 should receive HAART first, then vaccinate when CD4 rises above 200/μL 1

For Hepatitis C:

• Screen using enzyme immunoassays (EIAs) for anti-HCV antibody 1
• Positive anti-HCV results require verification with recombinant immunoblot assay (RIBA) or RT-PCR for HCV RNA 1
• Test for HCV RNA in patients with undetectable antibody but unexplained elevated liver enzymes or when acute HCV infection is suspected 1

Additional Baseline Testing:

• Complete blood counts with platelets, hepatic panel, and prothrombin time 1
• Baseline AFP and ultrasound in high-risk patients for hepatocellular carcinoma screening 1
• Consider liver biopsy for patients meeting criteria for chronic hepatitis to grade and stage disease 1

Ongoing Monitoring Strategy

For Patients Not on Treatment:

HBeAg-positive patients with HBV DNA >20,000 IU/mL and normal ALT 1:

• ALT every 3-6 months, more frequently if ALT becomes elevated 1
• If ALT 1-2× ULN, recheck every 1-3 months; consider liver biopsy if age >40 or persistently elevated 1
• If ALT >2× ULN for 3-6 months, consider liver biopsy and treatment 1

Inactive HBsAg carriers 1:

• ALT every 3 months for 1 year, then every 6-12 months if persistently normal 1
• If ALT >1-2× ULN, check HBV DNA and exclude other causes 1

For Patients on ART:

Monitor liver enzymes carefully but do not routinely withhold HAART from coinfected patients 1

After stopping ART with liver enzyme elevation 6:

• Check liver enzymes (AST, ALT, γ-glutamyltransferase) every 2 weeks initially, then monthly for first 3 months 6
• Monitor serum bicarbonate and electrolytes every 3 months for early identification of increased anion gap 6
• Measure serum lactate if lactic acidosis suspected (using prechilled fluoride-oxalate tubes, processed within 4 hours) 6

Management Strategies for Coinfected Patients

HIV/HBV Coinfection:

Severe acute exacerbations of hepatitis B can occur after discontinuing emtricitabine and/or tenofovir-containing regimens 8, 9:

• Closely monitor hepatic function with clinical and laboratory follow-up for at least several months after discontinuation 8, 9
• Anti-hepatitis B therapy may be warranted if appropriate 8, 9

HIV/HCV Coinfection:

Patients with chronic HCV should be vaccinated against hepatitis A 1:

• Risk for fulminant hepatitis with hepatitis A is increased in HCV-coinfected persons 1
• 66-75% of HIV patients develop protective antibody responses despite reduced immunogenicity 1
• Prevaccination screening for hepatitis A antibody is cost-effective when >30% prevalence expected (e.g., persons >40 years) 1

Patients should also be vaccinated for hepatitis B if susceptible 1

Alcohol counseling is critical 1:

• Coinfected patients should be advised not to drink excessive amounts of alcohol 1
• Avoiding alcohol altogether is prudent as even occasional use (<12 ounces beer or <10 grams alcohol/day) may increase cirrhosis risk 1

Treatment Considerations:

HIV/HCV coinfected patients should be evaluated for chronic liver disease and possible treatment 1:

• Direct-acting antivirals (DAAs) are first-line therapy, treating coinfected patients identically to HCV monoinfection 10
• DAAs are strongly preferred over interferon-based regimens due to higher efficacy and better tolerability 10
• Care should be coordinated by providers with experience treating both HIV and HCV infections 1

Antiretroviral therapy should be started or continued in all HIV/chronic liver disease patients regardless of CD4 count 10:

• Benefits of immune recovery outweigh risks of drug toxicity 10
• ART should not be interrupted as discontinuation increases risk of opportunistic infections, death, and accelerated liver disease progression 10
• Recovery of immune function through ART delays liver disease progression by reducing HIV-related immune activation 10

Preferred ART Regimens for Liver Disease:

Integrase inhibitors (dolutegravir, raltegravir, bictegravir) are preferred 6, 10:

• Superior hepatic safety profiles 6
• Minimal drug-drug interactions 10
• No dose adjustment required in severe hepatic impairment 6

Rilpivirine can be used safely with minimal hepatotoxicity risk 10

Efavirenz-based regimens show lower hepatotoxicity risk than nevirapine 6

Common Pitfalls to Avoid

• Never test only HBsAg for HBV screening—occult HBV requires anti-HBc testing as well 1
• Do not vaccinate for hepatitis B when CD4 <200/μL—wait until immune reconstitution occurs 1
• Never rechallenge with nevirapine after documented hepatotoxicity—this can be fatal 6
• Do not routinely withhold HAART from coinfected patients due to fear of hepatotoxicity—the benefits outweigh risks 1
• Avoid combining ribavirin with zidovudine or didanosine due to severe toxicity risks 10
• Do not use lovastatin or simvastatin with protease inhibitors due to rhabdomyolysis risk 10
• Never interrupt ART due to risk of immunologic compromise, opportunistic infection, and death 10